PDS Biotechnology Corp logo

PDS Biotechnology Corp

FRA:EU6 (USA)  
€ 3.01 (+0.94%) Apr 26
At Loss
P/B:
4.13
Market Cap:
€ 111.81M ($ 119.66M)
Enterprise V:
€ 81.32M ($ 87.03M)
Volume:
-
Avg Vol (2M):
837.00
Also Trade In:

Business Description

Description
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Name Current Vs Industry Vs History
Cash-To-Debt 2.37
Equity-to-Asset 0.44
Debt-to-Equity 0.91
Debt-to-EBITDA -0.59
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 63.62
9-Day RSI 49.35
14-Day RSI 43.11
6-1 Month Momentum % 14.53
12-1 Month Momentum % -21.61

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.33
Quick Ratio 4.33
Cash Ratio 4.15

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -14.1
Shareholder Yield % -23.27